Universitätsklinikum Münster

Hospital


Location: Münster, Germany (DE) DE

ISNI: 0000000405514246

ROR: https://ror.org/01856cw59

Show on Map:


Clinical Outcome and Quality of Life of Multimodal Treatment of Extracranial Arteriovenous Malformations: The APOLLON Study Protocol (2022) Schmidt VF, Masthoff M, Vielsmeier V, Seebauer CT, Cangir O, Meyer L, Muekke A, et al. Journal article Eculizumab use in neuromyelitis optica spectrum disorders: real-world evidence from Germany and Austria (2022) Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Ozalp SH, Lohmann L, et al. Conference contribution S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus (2022) Ständer S, Zeidler C, Augustin M, Darsow U, Kremer A, Legat FJ, Koschmieder S, et al. Journal article S2k guideline: Diagnosis and treatment of chronic pruritus (2022) Ständer S, Zeidler C, Augustin M, Darsow U, Kremer A, Legat FJ, Koschmieder S, et al. Journal article Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial (2022) Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, et al. Journal article Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) Kunadt D, Stasik S, Metzeler KH, Roellig C, Schliemann C, Greif PA, Spiekermann K, et al. Journal article CFAP74-mutations as cause of Primary Ciliary Dyskinesia (PCD): Clinical presentation and diagnostic challenges (2022) Biebach L, Cindric S, Koenig J, Aprea I, Dougherty G, Raidt J, Bracht D, et al. Conference contribution Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey (2022) Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, et al. Journal article Mutations in CFAP74 as a cause of primary ciliary dyskinesia (PCD) with normal nasal NO production rate and normal ciliary ultrastructure (2022) Biebach L, Cindric S, Koenig J, Aprea , Dougherty G, Raidt J, Bracht D, et al. Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution